Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims match the provided FDA label excerpts (brand name and active ingredient consistent; indication as chronic angina). However, the response does not provide label-supported language for generic/non-brand naming, and it omits that Ranexa is specifically an extended-release tablet in the claim set.
Category Scores
Accurate Statements
Ranolazine is used to treat chronic (long-term) angina (chest pain) in certain patients.
Indications and Usage: "Ranexa is indicated for the treatment of chronic angina."
Ranolazine is the active ingredient in Ranexa.
Label context throughout provided excerpts refers to "Ranexa (ranolazine)" (e.g., Indications and Usage and QT warning sections).
Ranexa is a brand-name medication.
Provided label excerpts refer to "Ranexa" as the drug name (e.g., "Ranexa is indicated..."), consistent with brand labeling context.
Unsupported Statements
Ranexa’s generic (non-brand) name is ranolazine.
The supplied label excerpts provided in the prompt do not explicitly state the generic/non-brand name mapping as phrased; they only show ranolazine as the active ingredient in the context of "Ranexa (ranolazine)".
Contradictions
Important Omissions
That Ranexa is specifically formulated as extended-release tablets ("extended-release tablets" is listed in the user-provided non-label section but was not addressed within the claim set).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Claims evaluated are limited to identification and indication; no dosing, contraindications, warnings, or interaction recommendations were made in the AI claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The generic-name equivalence statement is not explicitly supported by the supplied label excerpts as phrased.
Suggested Improvement
Rephrase the generic-name claim to rely on label-supported wording (e.g., indicate that Ranexa contains ranolazine as the active ingredient) rather than asserting the generic/non-brand name mapping.